Monographie - Bortezomib

Seneste opdatering :
29/10/2024

Bortezomib

Kemisk struktur

Handelsnavn

Handel navne er vejledende og hjælpestoffer sammensætning kan være forskellig afhængigt af landet og laboratorier

Bemoncaz	Mexico
Bicavan	Chile
Biemib	Tyrkiet
Bomib	Mexico
Borater	Argentina
Borcade	Tyrkiet
Bormib	Argentina
Bortezomib	New Zealand
Bortezun	Ecuador
Bortrac	Ecuador, Marokko
Bortzo	Marokko
Botemib	Chile, Ecuador, Marokko
Bozix	Chile, Marokko
Bozob	Argentina, Ecuador, Marokko
Bromadene	Argentina
Egybort	Indien
Elomaziv	Mexico
Gysatri	Argentina
Miasoma	Argentina
Mibor	Marokko
Multizom	Argentina
Rebtik	Chile
Velcade	Argentina, Australien, Belgien, Canada, Chile, Colombia, Danmark, Finland, Forenede Arabiske Emirater, Frankrig, Grækenland, Holland, Irland, Island, Italien, Japan, Luxemborg, Malaysia, Mexico, New Zealand, Norge, Polen, Portugal, Rumænien, Saudi-Arabien, Schweiz, Spanien, Storbritanien, Sverige, Tyrkiet, Tyskland, Ungarn, USA, Venezuela, Ægypten, Østrig
Velcord	Marokko
Vortemyel	Rumænien
Zefra	Argentina
Zegomib	Rumænien
Zuricade	Mexico

Bibliografi : Bortezomib

	Type	offentliggørelse
1911	Laboratorium	Bortezomib (Velcade®) - Summary of Product Characteristics Janssen-Cilag Ltd 2016
2010	Journal	André P, Cisternino S, Chiadmi F, Toledano A, Schlatter J, Fain O, Fontan JE. Stability of bortezomib 1 mg/ml solution in plastic syringe and glass vial. Ann Pharmacotherapy 2005 ; 39: 1462-1466.
2011	Journal	Friess D, Nguyen HC, Lipp HP. HPLC-stabilitätuntersuchungen zu rekonstituierten Bortezomib-Lösungen. Krankenhauspharmazie 2005 ; 26, 6: 206-210.
2232	Journal	Walker SE, Milliken D, Law S. Stability of Bortezomib Reconstituted with 0.9% Sodium Chloride at 4°C and Room Temperature (23°C) Can J Hosp Pharm 2008 ; 61, 1: 14-20.
3190	Journal	Bolognese A, Esposito A, Manfra M, Catalano L, Petruzziello F, Martorelli MC, Pagliuca R, Mazzarelli V, Ottiero M, Scalfaro M, An NMR Study of the Bortezomib Degradation under Clinical Use Conditions. Advance in Haematology 2009 Article ID 704928, 5 page
3240	Poster	Perissutti M, Vigneron J, Zenier H, May I, Demoré B. Etude de la stabilité d'une solution de bortézomib à 1 mg/mL conditionnée en seringue de polypropylène. Congrès SFPO 2011
3337	Journal	Carati D, Masini C, Minguzzi M, Petocchi B, Romanazzi C, Rondoni C, Sangiorgi E, Sferra S, Simonetta S, Stancari A, Locchi F, Z Stability of bortezomib reconstituted under clinical use conditions in original vials and polypropylene syringes at 4 °C and room temperature. EJHP 2012 ; 19: 428-431.
3349	Journal	Bosch-Ojeda C, Sanchez-Rojas M.F, Espinosa-Bosch M. Chemical stability of bortezomib solutions in original manufacturer vials. Int J Pharm Bio Sci 2012 ; 2, 3: 344-350.
3418	Journal	Berruezo garcia J, Espinosa Bosch M, Sanchez Rojas F, Bosch Ojeda C Chemical stability of bortezomib solutions in original manufacturer vial at room temperature and in syringe at 4°C. Int J Pharm Bio Sci 2013 ; 3, 1: 449-458.
3447	Poster	Giovanelli M, Vigneron J, May I, Nicolas A. Etude de la stabilité d’une solution de bortézomib à 2,5 mg/mL par chromatographie liquide à haute performance couplée à un détecteur à barrettes de diodes et à un détecteur évaporatif à diffusion de lumière. SFPO Congress, Mandelieu, France 2013
3537	Journal	Lipp HP, Gfrörer W, Riedmüller S. Bortezomib zur subkutanen Applikation. Krankenhauspharmazie 2013 ; 34,11: 500-505.
3688	Journal	Walker S.E, Charbonneau L.F, Law S. Stability of bortezomib 2.5 mg/mL in vials and syringes stored at 4°C and room temperature (23°C). Can J Hosp Pharm 2014 ; 67, 2: 102-107
4137	Journal	Patel T, Sewell G. Short Report : Extended Stability Studies on Bortezomib Injection and Infusions of Cisplatin and Pemetrexed (all Accord Healthcare). Newsletter Stabilis 2018 41;2-6
4485	Journal	Law S, Charbonneau L, Iazetta J, Perks W, Ma N, Walker S.E. Stability of Generic Formulations of Bortezomib 1.0 and 2.5 mg/mL in Vials and Syringes Stored 4°C and Room Temperature (23°C) Can J Hosp Pharm 2021 ;74;1:57-69

Mentions Légales